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Introduction
Renal cell carcinoma (RCC) is frequently divided histologi-
cally into clear cell (ccRCC) and nonclear cell RCC. ccRCC 
is the most prevalent form of RCC, accounting for 75–80% 
of cases, while papillary RCC (pRCC) is the most com-
mon variant of nonclear cell RCC, constituting 10–15% 
of all RCCs [1, 2]. pRCC is a heterogeneous disease that 
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Abstract
Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly 
characterized in the era of targeted therapy. A total of 5474 patients with meta-
static renal cell carcinoma (mRCC) in the International mRCC Database Con-
sortium (IMDC) were retrospectively analyzed. Outcomes were compared between 
clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded 
type I and type II papillary patients (n = 30 and n = 165, respectively). Overall 
survival (OS), progression- free survival (PFS), and overall response rate (ORR) 
favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and 
the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS 
or ORR were detected between type I and II PRCC in this limited dataset. The 
median OS for type I pRCC was 20.0 months while the median OS for type 
II was 12.6 months (P = 0.096). The IMDC prognostic model was able to 
stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate 
risk (OS = 17.0 months), and poor- risk groups (OS = 6.0 months). pRCC 
patient outcomes were inferior to ccRCC, even after controlling for IMDC 
prognostic factors. The IMDC prognostic model was able to effectively stratify 
pRCC patients.
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can be further divided into two main subtypes based on 
histopathologic features. Type I tumors typically consists 
of thin, basophilic papillae cells, whereas type II pRCC 
have thicker papillae and an eosinophilic cytoplasm [3]. 
Unlike ccRCC, pRCC is not associated with aberrations 
of the VHL gene. Instead, type I pRCC frequently displays 
alterations of the MET gene, whereas type II tumors are 
associated with alterations of the NRF2- ARE pathway and 
the fumarate hydratase gene [4, 5]. Some type II pRCC 
tumors may also exhibit increased MET expression [5].
Patient outcomes for pRCCs are not well documented, 
especially when treated with targeted therapy. Localized 
pRCC may have a better prognosis than localized ccRCC, 
but several large studies have reported conflicting results 
[1, 6–8]. Outcomes for metastatic pRCC patients are even 
less well characterized, but several smaller studies suggest 
that ccRCC histology is more favorable than pRCC histol-
ogy [9, 10]. The past decade has seen the treatment of 
metastatic RCC shift from cytokine- based immunotherapy 
to targeted therapies, however, the major clinical trials 
leading to this paradigm shift primarily included ccRCC 
patients. Given the distinct genetic differences between 
pRCC and ccRCC, it is not surprising that therapies tar-
geting the vascular endothelial growth factor (VEGF) and 
the mammalian target of rapamycin (mTOR) have failed 
to benefit pRCC patients to the same extent as ccRCC 
patients [9]. To date, there is no standard treatment for 
pRCC.
The outcomes for metastatic type I and type II pRCC 
are poorly understood and the majority of clinical trials 
including pRCC patients often do not distinguish between 
the subtypes. This study was designed to retrospectively 
determine the outcomes of metastatic pRCC patients as 
compared to ccRCC patients treated with targeted thera-
pies, and to compare the outcomes of metastatic type I 
and type II disease. To the best of the author’s knowledge, 
this is the largest analysis of metastatic pRCC and its 
subtypes to date.
Materials and Methods
Patient population and histology
Twenty- seven international cancer centers in Canada, the 
USA, Denmark, Greece, South Korea, Australia, New 
Zealand, Japan, Singapore, Belgium, and Italy provided 
consecutive patient data collected from hospital and phar-
macy records using uniform database software and tem-
plates. Data were collected between 2005 and May 2016. 
Institutional review board approval was obtained from 
each participating center.
All patients were diagnosed with mRCC and were treated 
with at least one approved VEGF (sunitinib, sorafenib, 
pazopanib, bevacizumab, or axitinib) or mTOR- targeted 
therapy (temsirolimus or everolimus). Only patients diag-
nosed with clear cell or papillary histology were included. 
Tumor histology was recorded in the data collection tem-
plate using pathology reports from each respective institu-
tion. These pathology reports were completed by 
pathologists prior to and independently from this study 
as a part of routine diagnosis. Subtypes were only recorded 
as type I or type II if explicitly stated on the pathology 
report. Some tumors were recorded as mixed type I/II 
histology. Reports that could not differentiate the subtype 
were recorded as not otherwise specified (NOS). Patients 
with the subtype unavailable were coded as not 
available.
Outcomes
The primary outcome was overall survival (OS) from date 
of initiation of targeted therapy, while secondary outcomes 
included progression- free survival (PFS) and response rate 
(RR). OS was defined as the time from initiation of tar-
geted therapy to death or censored at last follow up. PFS 
was defined as the time from initiation of targeted therapy 
until progression- based on Response Evaluation Criteria 
in Solid Tumors (RECIST) guidelines, cessation of therapy, 
death while on therapy, or censored at last follow- up 
[11].
The median OS associated with each first- line therapy 
was reported for pRCC patients. Additionally, VEGF and 
mTOR therapies were pooled separately to compare pRCC 
response to each drug class based on OS, PFS, and ORR.
To determine the utility of the International mRCC 
Database Consortium (IMDC) prognostic model in pRCC, 
patients were stratified into risk groups based on the 
IMDC prognostic factors: hemoglobin below the lower 
limit of normal (LLN), corrected calcium greater than 
the upper limit of normal (ULN), neutrophils above ULN, 
platelets above ULN, Karnofsky performance status (KPS) 
below 80%, and time from diagnosis to treatment of 
<1 year [12]. Patients with none, 1 or 2, and 3 or more 
prognostic factors are categorized as favorable, intermedi-
ate, and poor risk, respectively.
Statistical analysis
Statistical analyses were performed with SAS version 9.4 
(Cary, NC). Patient outcomes were compared between 
ccRCC and pRCC. A further analysis of pRCC was per-
formed to compare outcomes of type I and type II pRCC. 
Kaplan–Meier curves were constructed to estimate median 
OS and PFS; these outcomes were compared using the 
log- rank test. Cox regression modeling was performed for 
OS for pRCC versus ccRCC, adjusted using the individual 
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IMDC prognostic factors. Missing data were handled con-
servatively with the case deletion method. Best achieved 
RR was reported as complete response (CR), partial 
response (PR), stable disease (SD), and progressive disease 
(PD) as based on RECIST guidelines. CR and PR were 
pooled together as an overall response rate (ORR), which 
was then used to compare between treatment groups using 
Fischer’s exact test.
Results
Data from 5474 patients from the IMDC were retrospec-
tively analyzed. Our analysis included 5008 patients with 
clear cell histology and 466 with papillary histology. Of 
the 466 pRCC histologies, 30 (6.4%) were type I, 165 
(35.4%) were type II, 47 (10.1%) had mixed type I/type 
II features, 146 (31.3%) were not specified, and 78 (16.7%) 
had missing information on subtype. (Table 1) Considering 
only known and recorded subtype histologies (n = 242), 
11.5% were type I, 68.2% were type II, and 19.4% were 
mixed histology. ccRCC and pRCC patient characteristics 
are listed in Table 1.
OS, PFS, and RR all favored ccRCC over pRCC (Table 2). 
Median OS was over 8 months longer in ccRCC patients, 
21.9 months, as compared to 13.8 months in pRCC. When 
adjusted by the individual IMDC prognostic factors by 
Cox regression modeling, the hazard ratio of death for 
overall survival was 0.71 (95% CI 0.62–0.81, P < 0.0001) 
for patients with ccRCC versus patients with pRCC. PFS 
was 7.3 months in ccRCC and 4.7 months in pRCC. 
ORR to first- line therapy of any type was 30.6% in ccRCC 
and 10.3% in pRCC (P < 0.0001). PD was observed as 
the best response in 24.9% of ccRCC patients and 34.3% 
of pRCC patients.
The median OS for type I pRCC was 20.0 months 
while the median OS for type II was 12.6 months 
(P = 0.096) (Fig. 1). No differences in PFS were observed 
for type I and type II (Fig. 2). ORR to any targeted 
therapy was 9.1% (2/22) for type I patients and 14.3% 
(20/139) for type II.
For first- line treated pRCC patients, sunitinib was the 
most frequently used targeted therapy (63.9%), followed 
by sorafenib (12.9%), temsirolimus (12.4%) and everolimus 
(5.1%) (Table 3). No single targeted therapy appeared to 
provide a superior OS benefit. pRCC outcomes for OS 
and PFS were similar in patients treated with mTOR 
inhibitors and VEGF inhibitors (Table 3). However, ORR 
favored VEGF therapies (11.9%) over mTOR therapies 
(3.2%, P = 0.0413).
The IMDC prognostic model stratified pRCC patients 
into significantly different prognostic groups (P < 0.0001). 
Favorable- risk patients (0 factors) had an OS of 
34.1 months, intermediate- risk patients (1–2 factors) had 
an OS of 17.0 months, while poor- risk patients (three or 
more factors) had an OS of 6.0 months (Fig. 3).
Discussion
Until recently, the majority of data regarding pRCC has 
come from smaller retrospective analyses, subanalysis of 
clinical trials, expanded access trials, and phase II trials 
that combined pRCC with other nonclear cell RCCs [9, 
13–17]. The IMDC previously reported that metastatic 
pRCC has a worse outcome than ccRCC, a finding that 
we have confirmed in a sample size nearly three times 
larger [9]. This gap is likely to increase as further therapies 
are approved for ccRCC [18]. Our study was also able 
to analyze pRCCs by subtype and report that OS in type 
I pRCC may be similar to ccRCC, but that a high degree 
of variance exists within this population. Despite our study 
including the largest reported number of type I patients 
to date, it remains difficult to draw firm conclusions from 
only 30 patients. Only two clinical trials, SUPAP 
(NCT00541008) and RAPTOR (NCT00688753), have 
enrolled pRCC patients by subtype, but each enrolled only 
15 and 13 type I patients, respectively [19, 20]. Metastatic 
type I tumors appear to be far less common than type 
II, and are consequently more difficult to study. This 
may be related to previously reported findings that local-
ized type II tumors often present with higher TNM staging 
than type I tumors [21–23].
Table 1. Baseline characteristics of ccRCC (clear cell renal cell carcino-
ma) and papillary renal cell carcinoma (pRCC) patients.
Baseline characteristics ccRCC n (%) pRCC n (%)
Male 3685/5008 (73.6%) 366/466 (78.5%)
Nephrectomy 4134/4999 (82.7%) 384/466 (82.4%)
IMDC prognostic group
Favorable 783/3919 (20.0%) 43/359 (12.0%)
Intermediate 2165/3919 (55.2%) 200/359 (55.7%)
Poor 971/3919 (24.8%) 116/359 (32.3%)
Histology
Type I N/A 30/466 (6.4%)
Type II 165/466 (35.4%)
Mixed 47/466 (10.1%)
NOS 146/466 (31.3%)
Data unavailable 78/466 (16.7%)
KPS <80 949/4604 (20.6%) 96/419 (22.9%)
Diagnosis- to- 
treatment <1 year
2617/5003 (52.3%) 280/466 (60.1%)
Hemoglobin <LLN 2502/4677 (53.5%) 272/425 (64%)
Platelet >ULN 716/4554 (15.7%) 86/423 (20.3%)
Neutrophil >ULN 651/4553 (14.3%) 91/418 (21.8%)
Calcium >ULN 597/4306 (13.9%) 47/390 (12.1%)
>1 Metastasis 3711/4930 (75.3%) 344/463 (74.3%)
Brain metastasis 398/4860 (8.2%) 16/441 (3.6%)
NOS, not otherwise specified; KPS, Karnofsky performance status; LLN, 
lower limit of normal; ULN, upper limit of normal.
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The activity of targeted therapies in pRCC has varied 
between studies, but in general, outcomes are thought to 
be better in metastatic ccRCC than in metastatic pRCC 
[9]. Our results demonstrate that ccRCC patients had 
better OS, PFS, and RR when treated with targeted therapy 
than pRCC patients. Within pRCC, no survival differences 
Table 2. Outcomes in response to targeted therapy for ccRCC (clear cell renal cell carcinoma) and papillary renal cell carcinoma (pRCC).
ccRCC (n = 5008) pRCC (n = 466) P- value
OS (months; 95% CI) 21.9 (20.9–22.9) 13.8 (12.5–16.1) 0.0001
PFS (months; 95% CI) 7.3 (6.9–7.7) 4.7 (4.1–5.2) 0.0001
RR to 1st Line TT n (%) n (%) <0.0001
Complete response 110/4389 (2.5%) 3/391 (0.8%)
Partial response 1234/4389 (28.1%) 37/391 (9.5%)
Stable disease 1950/4389 (44.4%) 217/391 (55.5%)
Progressive disease 1095/4389 (24.9%) 134/391 (34.3%)
OS by IMDC prognostic group (months; 95% CI)
Favorable 41.9 (38.0–44.8) (n = 783) 34.1 (18.6–49.1) (n = 43) 0.40
Intermediate 24.0 (22.8–25.1) (n = 2165) 17.0 (13.4–18.7) (n = 200) 0.0001
Poor 7.1 (6.5–8.0) (n = 971) 6.0 (4.1–7.9) (n = 116) 0.03
OS, overall survival; PFS, progression- free survival; RR, response rate; TT, targeted therapy; IMDC, International mRCC database consortium; CI, 
Confidence interval.
Figure 1. Kaplan–Meier curve depicting the overall survival of type I (n = 30) and type II (n = 165) metastatic papillary renal cell carcinoma patients 
treated with targeted therapy.
Figure 2. Kaplan–Meier curve depicting the progression- free survival of type I (n = 30) and type II (n = 165) metastatic papillary renal cell carcinoma 
patients treated with targeted therapy.
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were detected between VEGF agents and mTOR agents, 
however VEGF therapies had a more favorable ORR. 
Although difficult to compare across studies due to het-
erogeneous patient populations, ORR to sunitinib has been 
previously reported to range between 0–24%, with the 
exception of one Korean study in which the ORR was 
36% [14, 24–27]. ORR to everolimus has yet to surpass 
7% [27–29]. In our analysis, the majority of mTOR- treated 
patients received temsirolimus rather than everolimus. This 
was likely due to the influence of a subgroup analysis of 
a phase III trial that reported an improved clinical benefit 
of temsirolimus over interferon alpha in patients with 
nonclear histology [17].
Despite mTOR inhibitors potentially having a lower 
ORR than VEGF inhibitors in pRCC patients, studies to 
date have not been powered to detect a difference in 
survival outcomes. Two recent randomized phase II clini-
cal trials tested first- line everolimus versus sunitinib in 
nonclear RCC patients. ASPEN included 70 pRCC patients 
and found sunitinib to have a higher ORR (24% vs. 5%) 
and a longer median PFS (8.1 months vs. 5.5 months) 
than everolimus, but reported no difference in OS [27]. 
The ESPN trial included 27 pRCC patients. Everolimus 
displayed a median PFS of 4.1 months and a median OS 
of 14.9 months, both of which were not superior to suni-
tinib, which had a median PFS of 5.7 months and a 
median OS of 16.6 months [24]. In our study the 23 
patients receiving everolimus reached higher OS 
(26 months) than patients being treated with sunitinib 
(15 months) but no robust statements can be made given 
the small numbers of patients treated with everolimus.
Only two phase II trials have been conducted that spe-
cifically limited enrollment to pRCC patients and analyzed 
by subtype. The SUPAP trial studied first- line sunitinib 
in 15 type I and 46 type II pRCC patients, while the 
RAPTOR trial has reported interim per protocol results 
on 13 type I and 40 type II patients treated with first- line 
everolimus. SUPAP reported similar ORRs to sunitinib, 
11% and 13% for type I and type II, respectively. Median 
PFS was 6.6 months (95% CI 2.8–14.8) in type I and 
5.5 months (95% CI 3.8–7.1) in type II [19]. Median 
OS was 17.8 months (95% CI 5.7–26.1) for type I and 
12.4 months (95% CI 8.2–14.3) for type II. Treatment 
with everolimus in the RAPTOR trial has so far resulted 
in a median PFS of 6.2 months (95% CI 2.1–9.9) for 
type I and 3.7 months (95% CI 1.9–5.7) for type II [20]. 
Median OS was 28.0 months (95% CI 4.0–28.0) in type 
I and 20.0 months (95% CI 11.0- NR) in type II [20].
While sunitinib was the most predominately used tar-
geted therapy in this study, it is important to note that 
the data collection period spans from 2004–2016, thus 
trends will inevitably shift based on the approval of addi-
tional agents. Of note are several upcoming clinical trials 
Figure 3. Kaplan–Meier curve depicting the overall survival of 359 metastatic papillary renal cell carcinoma stratified by International mRCC Database 
Consortium- risk factor group. Blue = favorable risk (12.0%), Red = intermediate risk (55.7%), Green = poor risk (32.3%).
Table 3. Outcomes in papillary renal cell carcinoma (pRCC) patients 
treated with first- line targeted therapy.
First- line therapy (n, %) OS (months, 95% CI)
Sunitinib (288/451 63.9%) 14.9 (12.6–18.2)
Sorafenib (58/451, 12.9%) 11.7 (8.1–20.9)
Bevacizumab (5/451, 1.1%) 16.7 (14.0–20.4)
Temsirolimus (56/451, 12.4%) 11.8 (7.8–14.5)
Everolimus (23/451, 5.1%) 26.0 (8.0–41.7)
Pazopanib (21/451, 4.7%) 11.5 (3.1–14.9)
Outcome mTOR inhibitors VEGF inhibitors P- value
OS (months; 
95% CI)
12.4 (8.9–18.2) 
(n = 77)
13.9 (12.5–16.7) 
(n = 377)
NS
PFS (months; 
95% CI)
3.7 (2.7- 5.3) 
(n = 76)
4.9 (4.2- 5.4) 
(n = 378)
NS
ORR (CR + PR) 2/63 (3.2%) 38/320 (11.9%) P = 0.0413
OS, overall survival; PFS, progression- free survival; ORR, overall response 
rate; CR, complete response; PR, partial response; NS, not statistically 
significant; CI, confidence interval; mTOR, mammalian target of rapa-
mycin; VEGF, vascular endothelial growth factor.
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focusing exclusively on pRCC patients. These include the 
final results of the phase II RAPTOR trial (first- line 
everolimus monotherapy; NCT00688753), the ongoing 
phase II AXIPAP trial (first- line axitinib; NCT02489695), 
and the ongoing PAPMET trial (NCT02761057). The 
PAPMET trial is a large, randomized phase II trial com-
paring four therapies: sunitinib, cabozantinib, crizotinib, 
and volitinib, for which the latter three target the MET 
pathway. MET pathway alterations were traditionally asso-
ciated with type I pRCC, however recent studies have 
identified that type II pRCCs can also display high- MET 
expression [4, 5]. The rationale for targeting MET in 
pRCC was previously demonstrated in a phase II trial 
with foretinib, a dual MET/VEGFR2 inhibitor, that pro-
duced an RR of 13.5% and a median PFS of 9.3 months 
[30]. Volitinib’s targeting of MET has also demonstrated 
potential utilization according to preliminary phase I/II 
trial results (NCT02127710); a phase III trial is planned 
[31]. Additionally, it is likely that PD- L1 inhibitors will 
be tested in pRCC in the near future, given evidence that 
~10% of pRCC tumors express PD- L1, and these patients 
appear to have worse outcomes than PD- L1 negative 
tumors [32].
In summary, there is no current standard of care for 
metastatic pRCC as the evidence to guide treatment deci-
sions is limited by small sample sizes. This is the largest 
analysis of metastatic pRCC and its subtypes to date. Our 
analysis is limited by its retrospective design and the lack 
of a centralized review, however such review was not 
feasible and our data is more reflective of standard daily 
practice. In addition, the authors acknowledge that sub-
typing of pRCC is becoming less dependent on histologic 
review but is instead shifting towards genetic analysis, 
which may explain some of the variance in subtype 
 outcomes [4].
Conclusion
This study provides more evidence that metastatic pRCC 
has worse OS, PFS, and RR outcomes as compared to 
ccRCC when treated with contemporary targeted therapy. 
In this dataset, type II pRCC was over five times more 
common than type I pRCC in metastatic disease. We 
found that type I pRCC outcomes were similar to ccRCC 
however a great deal of variance exists in this subgroup, 
preventing a firm conclusion that metastatic type I pRCC 
has a better prognosis than metastatic type II pRCC. 
Importantly, the IMDC prognostic model was effective 
in stratifying patients into favorable- , intermediate- , and 
poor- risk outcomes. Upcoming clinical trials may provide 
better guidance on management of pRCC patients but 
until better therapies are established, it is reasonable to 
offer pRCC patients targeted therapy.
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